Guerin 2000.

Methods	6‐Week placebo run‐in period 6‐Week before‐and‐after study
Participants	18 men and women with hypercholesterolaemia and hypertriglyceridaemia aged 35 to 75 years; TG > 150 mg/dL (1.69 mmol/L), TC > 230 mg/dL (5.95 mmol/L) Exclusion criteria: dysbetalipoproteinaemia, diabetes mellitus, secondary hyperlipidaemia, uncontrolled HTN or major cardiovascular event Baseline TC: 6.90 mmol/L (267 mg/dL) Baseline LDL‐C: 4.53 mmol/L (175 mg/dL) Baseline HDL‐C: 1.19 mmol/L (46 mg/dL) Baseline TG: 2.22 mmol/L (197 mg/dL)
Interventions	Atorvastatin 10 mg/d
Outcomes	Per cent change from baseline at 6 weeks of serum TC, LDL‐C, HDL‐C and TG
Notes	SDs were imputed
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, assessment of random sequence generation is not applicable
Allocation concealment (selection bias)	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, assessment of allocation concealment is not applicable
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, blinding status is not applicable
Incomplete outcome data (attrition bias) All outcomes	Low risk	Data on all participants were reported
Selective reporting (reporting bias)	Low risk	All lipid parameters were measured
Other bias	High risk	Parke‐Davis partially funded the study; data may support bias for atorvastatin